MedTrace Logo

Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19

NCT05054114 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 630

Last updated 2024-08-09

Study results available
· View outcomes & findings →

Summary

It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection. In this study the primary aim is to investigate 28-day regime of nasal interferon gama use in healthy participants for COVID-19 and other respiratory infections prevention.

Conditions

  • COVID-19 Respiratory Infection
  • Acute Respiratory Disease

Interventions

DRUG

Interferon gamma human recombinant (IFN-G)

nasal form

Sponsors & Collaborators

  • SPP Pharmaclon Ltd.

    lead INDUSTRY

Principal Investigators

  • Anatoly I Saulin, Master · SPP Pharmaclon Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-21
Primary Completion
2021-05-25
Completion
2021-09-02

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05054114 on ClinicalTrials.gov